explore -WSS

explore

author：focus 2025-09-03 14:38:18 - browse：25

Each COVID-19 vaccine vial from various companies is placed on individual rectangular backgrounds. Pfizer-BioNTech is positioned in the middle on a purple block adorned with two glitter star stickers, Moderna is on the top right on a red block, Janssen is on the bottom right on a blue block, and AstraZeneca is on the left on a red block. — Illustration: Christine Kao/STAT; Photos: Getty

It’s been four years since Covid-19 emerged, igniting a pandemic that killed millions of people and brought the world to its knees. A key factor in taming the pandemic was the creation of effective vaccines, which have saved millions of lives.

You’d think developing a successful vaccine would be an unmitigated win, from a financial perspective. And, indeed, for Pfizer and its partner BioNTech, as well as for Moderna — whose vaccines were the most widely used in the United States and much of the world — the revenues generated were absolutely staggering. But investors have shrugged at those sales as gains that will not be repeated.

Total sales of the Pfizer/BioNTech vaccine surpassed $80 billion, and more than 400 million doses of the shot and subsequent boosters have been administered in the U.S. alone. But the company’s stock price fell 32% over the past five years. Meanwhile, AstraZeneca, which told STAT it has not booked sales from its vaccine since last April and does not expect future sales, has seen its share price rise 64%. Merck, which saw its vaccine efforts fail twice, is up 56%.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Alabama IVF ruling threatens families facing fatal genetic disease

hotspot

WSS

He's a Nobel laureate. Critics say he was misleading on Covid

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

Hospitals consider fixing cancer drug shortages on their own

In utero gene editing: an explainer

knowledge

explore

explore

What does generative AI mean for health care? We asked experts

Antivenom research: Lessons from HIV applied in search for universal antidote

Peter Hotez and the public health issue of online harassment

Hospitals consider fixing cancer drug shortages on their own

Medicare details structure of new drug price negotiation program

PBM reform efforts get punted in Congress

Tori Bowie and the unacceptable rates of Black maternal death

FDA panel endorses Alnylam’s heart drug — after picking it apart

Cancer drug shortages should be causing more outrage

How housing is health care on Long Island

knowledge

What to make of Biden’s latest efforts on cancer research

He's a Nobel laureate. Critics say he was misleading on Covid

WATCH: Why do bright lights make us see spots?

IRA could hurt research into orphan drugs for rare diseases

Private equity could exacerbate cardiology's overuse problem, experts fear

Ed Silverman on new gene therapies, biosimilars, coffee, and more

focus

hotspot

Wikipedia

leisure time